Sucroferric Oxyhydroxide

Unknown Manufacturer

Indications

用于治疗12岁及以上CKD 4-5期（定义为肾小球滤过率<30mL/min/1.73m2）或接受透析的CKD儿科患者的高磷血症。

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Pharmaceutical composition, comprising phosphate binder particles
US 10624855 B2Applicant: VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTDPriority: 2013
US
5 publications
Particles of a mixture of iron(III)-oxyhydroxide, sucrose and one or more starches, preferably of sucroferric oxyhydroxide
US 12329778 B2Applicant: VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTDPriority: 2020
EP
US
WO
4 publications
Sucroferric oxyhydroxide-containing granules and pharmaceutical composition
US 12171878 B2Applicant: KISSEI PHARMACEUTICALPriority: 2018
US
WO
3 publications